Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ZIP7/SLC39A7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC39A7 Recombinant Protein (Functional Loop Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 expressed. |
View SLC39A7 Products |
| Gene Delivery | SLC39A7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer, sequence verified. |
View SLC39A7 Products |
| Benchmark Ab | Anti-SLC39A7 Recombinant Antibody Recombinant positive control for flow cytometry, IHC, and western blot. |
View SLC39A7 Products |
| Validator | SLC39A7 siRNA Set For knockdown verification in functional zinc-flux assays. |
View SLC39A7 Products |
| Related Target A | SLC39A6 (ZIP6) Forms functional heterodimers with ZIP7 to mediate zinc influx and drive EMT in breast cancer. |
View SLC39A6 Products |
| Related Target B | EGFR Downstream tyrosine kinase activated by ZIP7-mediated zinc release; key pathway in tamoxifen resistance. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass ER membrane topology validation | Lentivirus Premade Particles for stable cell lines preserving native intracellular localization |
| Subfamily counter screening (ZIP family specificity) | Homolog panel (including ZIP6/SLC39A6) verified by mass spectrometry and sequence alignment |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ZIP7/SLC39A7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ZIP7/SLC39A7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule intracellular inhibitors and targeted degraders. As first-generation therapies reach the clinic, the next wave of R&D is targeting ER-stress pathways and overcoming endocrine resistance in breast cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Academic Consortia | Tamoxifen-Resistant Breast Cancer, Colorectal Cancer | Intracellular Zinc Flux Assay (Need Lentivirus for Stable Cell Line) |
| Monoclonal Antibodies | Biotech Startups | Autoimmune Diseases (B-cell mediated) | Epitope Mapping & Specificity (Need Recombinant Loop Proteins) |
| siRNA / RNAi | RNA Therapeutics Specialists | Solid Tumors (Overexpressing ZIP7) | In vitro Knockdown Validation (Need High-Purity siRNA Sets) |